

CHAMPVA POLICY MANUAL

CHAPTER: 2
SECTION: 3.4
TITLE: IMMUNOTHERAPY FOR MALIGNANT DISEASE

AUTHORITY: 38 CFR 17.272(a)

RELATED AUTHORITY: 32 CFR 199.4(g)(15)

I. EFFECTIVE DATE

A. October 12, 1984

B. Effective March 6, 1986, Bacillus Calmette-Guerin (BCG) vaccine in intravesical immunotherapy for treatment of Stage O and Stage A carcinoma of the bladder may be cost shared.

II. PROCEDURE CODE(S)

90799

III. DESCRIPTION

The treatment of malignant disease by administration of purified antigen, autogenous vaccine, performed antibodies, purified protein derivatives, "deblocking proteins", immunizing agents, and live bacteria vaccines.

IV. POLICY

Immunotherapy for malignant diseases is considered investigational and is not covered, except as indicated below. This includes all associated pathology and radiology service performed to determine antibody levels, and all other related services and supplies.

V. EXCLUSIONS

Autolymphocyte therapy (ALT) or immunotherapy when used for treating metastatic kidney cancer patients.

END OF POLICY